AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26139360 — intervention group
Group type: EXPERIMENTAL
Intervention: True facilitative KINTAPE
Number of subjects: 64
Study 26139360 — intervention group
Group type: COMPARATOR
Intervention: Sham KINTAPE
Number of subjects: 64
Study 26139360 — intervention group
Group type: COMPARATOR
Intervention: No KINTAPE
Number of subjects: 64
Study 24277927 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (6 mg/kg)
Number of subjects: 17
Study 24277927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22492028 — intervention group
Group type: EXPERIMENTAL
Intervention: Perirhinal-lateral entorhinal pathway
Number of subjects: 28
Study 22492028 — intervention group
Group type: EXPERIMENTAL
Intervention: Parahippocampal-medial entorhinal pathway
Number of subjects: 28
Study 22492028 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior hippocampus
Number of subjects: 28
Study 20620788 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring donor-site block (20-mL injection of 0.25% bupivacaine)
Number of subjects: 27
Study 20620788 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (no hamstring donor-site block)
Number of subjects: 27
Study 18818444 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=8) - treadmill walking with rotating visual scene
Number of subjects: 16
Study 18818444 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=8) - treadmill walking with static visual scene
Number of subjects: 16
Study 16115337 — intervention group
Group type: EXPERIMENTAL
Intervention: VPP and IPP 1.8 mg
Number of subjects: 131
Study 16115337 — intervention group
Group type: EXPERIMENTAL
Intervention: VPP and IPP 2.5 mg
Number of subjects: 131
Study 16115337 — intervention group
Group type: EXPERIMENTAL
Intervention: VPP and IPP 3.6 mg
Number of subjects: 131
Study 16115337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 15544888 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 1600 mg
Number of subjects: 119
Study 15544888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 11060718 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cholinergic strategies
Number of subjects: 0
Study 11060718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement, anti-inflammatory agents, free radical scavengers, anti-oxidants, MAO-B inhibitors
Number of subjects: 0
Study 9196346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-bore catheters inserted to 5 cm
Number of subjects: 38
Study 9196346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-bore catheters inserted to 15 cm
Number of subjects: 38
Study 9196346 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters inserted into cephalic veins
Number of subjects: 38
Study 9196346 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheters inserted into basilic veins
Number of subjects: 38
Study 9196346 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of catheter lengths
Number of subjects: 38
Study 8225625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 89
Study 8225625 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus tobramycin
Number of subjects: 89
Study 3896455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with vincristin (1.2 mg/m2), Adriamycin (40 mg/m2), cyclophosphamide (500 mg/m2), and medroxyprogesteron acetate (MPA) (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Number of subjects: 155
Study 3896455 — intervention group
Group type: COMPARATOR
Intervention: Alternating therapy with the same combination chemotherapy (VAC) for three cycles alternating with MPA (600 mg orally on days 1-14, 500 mg intramuscularly on days 1-28, and twice weekly afterwards)
Number of subjects: 155
Study 3896455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 155
Study 3896455 — intervention group
Group type: COMPARATOR
Intervention: Alternating therapy
Number of subjects: 155
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: pethidine 1 mg/kg + atropine 0.01 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: COMPARATOR
Intervention: pethidine 1 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: d-tubocurarine 0.5 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: alcuronium 0.3 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.1 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg/kg
Number of subjects: 186
Study 2905566 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg/kg
Number of subjects: 186
Study 31431759 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual mapping training (24 six-hour sessions, 3 times a week)
Number of subjects: 81
Study 31431759 — intervention group
Group type: COMPARATOR
Intervention: Integration methods training (24 six-hour sessions, 3 times a week)
Number of subjects: 81
Study 27784211 — intervention group
Group type: EXPERIMENTAL
Intervention: FDSFs (Fast Dissolving Sublingual Films) containing Pullulan with Maltodextrin in a ratio 3:1
Number of subjects: 14
Study 27784211 — intervention group
Group type: EXPERIMENTAL
Intervention: FDSFs (Fast Dissolving Sublingual Films)
Number of subjects: 14
Study 27784211 — intervention group
Group type: COMPARATOR
Intervention: Ventolin® tablets 2 mg
Number of subjects: 14
Study 25319212 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 24196466 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical (intra-articular) tranexamic acid
Number of subjects: 157
Study 21572327 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotics administered before shock recognition
Number of subjects: 291
Study 21572327 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotics administered after shock recognition
Number of subjects: 291
Study 21572327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly delays in antibiotic administration after shock recognition
Number of subjects: 291
Study 19564218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar Disorder Center for Pennsylvanians (BDCP) study intervention
Number of subjects: 515
Study 17001209 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and health education program
Number of subjects: 0
Study 17001209 — intervention group
Group type: COMPARATOR
Intervention: Usual care (U)
Number of subjects: 0
Study 15228968 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based HIV/AIDS education
Number of subjects: 0
Study 15228968 — intervention group
Group type: COMPARATOR
Intervention: Counselor-delivered HIV/AIDS education
Number of subjects: 0
Study 11744790 — intervention group
Group type: EXPERIMENTAL
Intervention: York SF-12
Number of subjects: 2
Study 11744790 — intervention group
Group type: COMPARATOR
Intervention: SF-12
Number of subjects: 2
Study 9279722 — intervention group
Group type: EXPERIMENTAL
Intervention: PM inactivated hepatitis A vaccine
Number of subjects: 60
Study 9279722 — intervention group
Group type: COMPARATOR
Intervention: SB inactivated hepatitis A vaccine
Number of subjects: 60
Study 9279722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 60
Study 8393174 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-protein isolate, lactose-free formula with added soy polysaccharide (group SF, n = 19)
Number of subjects: 34
Study 8393174 — intervention group
Group type: COMPARATOR
Intervention: Same diet without added fiber (group S, n = 15)
Number of subjects: 34
Study 8393174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 3316656 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction (CAI)
Number of subjects: 0
Study 3316656 — intervention group
Group type: COMPARATOR
Intervention: Tutorials
Number of subjects: 0
Study 29778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-drinking test (WDT) in patients on medical treatment for POAG
Number of subjects: 122
Study 29778281 — intervention group
Group type: COMPARATOR
Intervention: Water-drinking test (WDT) in control group
Number of subjects: 122
Study 29778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (two or more medications)
Number of subjects: 122
Study 29778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin analogues
Number of subjects: 122
Study 29778281 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 122
Study 27351217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L treatment after 1L nab-P+Gem
Number of subjects: 347
Study 27351217 — intervention group
Group type: COMPARATOR
Intervention: 2L treatment after 1L Gem
Number of subjects: 347
Study 27351217 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L therapy containing fluoropyrimidine after 1L nab-P+Gem
Number of subjects: 347
Study 27351217 — intervention group
Group type: COMPARATOR
Intervention: 2L therapy containing fluoropyrimidine after 1L Gem
Number of subjects: 347
Study 25189213 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 25189213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 23775961 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (P) 500 mg/m²
Number of subjects: 205
Study 23775961 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Pemetrexed (CP) AUC 5 and 500 mg/m²
Number of subjects: 205
Study 20834082 — intervention group
Group type: COMPARATOR
Intervention: Quinine and placebo (Q+P)
Number of subjects: 50
Study 20834082 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine and rabeprazole (Q+R)
Number of subjects: 50
Study 18256069 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab at 3 and 5 mg/kg body weight administered over 24 weeks
Number of subjects: 138
Study 18256069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 15914575 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 40
Study 15914575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12942031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel therapy
Number of subjects: 27
Study 12942031 — intervention group
Group type: EXPERIMENTAL
Intervention: APAPFOT
Number of subjects: 27
Study 10481861 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with vepesid (group 2, trial 1)
Number of subjects: 408
Study 10481861 — intervention group
Group type: COMPARATOR
Intervention: Induction without vepesid (group 1, trial 1)
Number of subjects: 408
Study 10481861 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 45 mg/m2 (group 1, trial 2)
Number of subjects: 408
Study 10481861 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 60 mg/m2 (group 3, trial 2)
Number of subjects: 408
Study 10481861 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction with daunorubicin 45 mg/m2 (group 2, trial 2)
Number of subjects: 408
Study 8951922 — intervention group
Group type: EXPERIMENTAL
Intervention: High TENS (200 microseconds; 110 Hz)
Number of subjects: 48
Study 8951922 — intervention group
Group type: COMPARATOR
Intervention: Low TENS (200 microseconds; 4 Hz)
Number of subjects: 48
Study 8951922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8951922 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 1952845 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of ketoconazole alone
Number of subjects: 6
Study 1952845 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g of sucralfate with 400 mg of ketoconazole
Number of subjects: 6
Study 1952845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administered 2 h prior to 400 mg of ketoconazole
Number of subjects: 6
Study 6801962 — intervention group
Group type: EXPERIMENTAL
Intervention: FreAmine II
Number of subjects: 18
Study 6801962 — intervention group
Group type: COMPARATOR
Intervention: FreAmine III
Number of subjects: 18
Study 31736187 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (personalized guided imagery)
Number of subjects: 70
Study 31736187 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (personalized guided imagery)
Number of subjects: 70
Study 30169267 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4) - 15 μg haemagglutinin antigen per strain per 0.5 mL dose; single dose on day 0 for vaccine-primed children, and two doses on days 0 and 28 for vaccine-unprimed children.
Number of subjects: 12018
Study 30169267 — intervention group
Group type: COMPARATOR
Intervention: Non-influenza control vaccine (one or two doses).
Number of subjects: 12018
Study 30169267 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4
Number of subjects: 12018
Study 27221874 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (SQT)
Number of subjects: 100
Study 27221874 — intervention group
Group type: COMPARATOR
Intervention: 14-day standard triple therapy (STT)
Number of subjects: 100
Study 24262967 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine therapy
Number of subjects: 101
Study 22590982 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding duration
Number of subjects: 1403
Study 22590982 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding irrespective of consumption of other foods
Number of subjects: 1403
Study 22590982 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding duration longer than 6 months
Number of subjects: 1403
Study 20236432 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) providing ward-based rehabilitation after critical illness
Number of subjects: 0
Study 20236432 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA)
Number of subjects: 0
Study 20236432 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) service delivery model
Number of subjects: 0
Study 20236432 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic Rehabilitation Assistant (GRA) model
Number of subjects: 0
Study 17074778 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab disinfection with 2-propanol and benzalkonium chloride (SW)
Number of subjects: 70
Study 17074778 — intervention group
Group type: COMPARATOR
Intervention: Spray disinfection with 2-propanol and benzalkonium chloride (SP)
Number of subjects: 70
Study 15598453 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing knee flexion
Number of subjects: 10
Study 15598453 — intervention group
Group type: COMPARATOR
Intervention: Non-weight bearing knee flexion
Number of subjects: 10
Study 15598453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion with tibial internal rotation
Number of subjects: 10
Study 15598453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion with tibial external rotation
Number of subjects: 10
Study 12001325 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) as an adjuvant therapy
Number of subjects: 0
Study 12001325 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9787885 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT at 150% above initial seizure threshold
Number of subjects: 55
Study 9787885 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ECT
Number of subjects: 55
Study 9787885 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (both types)
Number of subjects: 55
Study 9787885 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute surge in oxytocin levels at the ninth ECT
Number of subjects: 55
Study 7897158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg, by mouth, daily)
Number of subjects: 7
Study 7897158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7897158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 7
Study 2698894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine periodontal ligament injections
Number of subjects: 28
Study 2698894 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine periodontal ligament injections
Number of subjects: 28
Study 2698894 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections
Number of subjects: 28
Study 4802389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 CCA unit Aichi/68 influenza vaccine
Number of subjects: 687
Study 4802389 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 CCA unit Japan/57 influenza vaccine
Number of subjects: 687
Study 31586833 — intervention group
Group type: EXPERIMENTAL
Intervention: Social contact
Number of subjects: 221
Study 31586833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy (MHL) conducted by clinicians
Number of subjects: 221
Study 31586833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy (MHL) conducted by dis-peer instructors
Number of subjects: 221
Study 27449500 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive peri-operative steroid combination (triamcinolone acetonide) 4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml into the sub-Tenon's space.
Number of subjects: 300
Study 27449500 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment and routine pre-operative and post-operative treatment and care.
Number of subjects: 300
Study 24789702 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered nursing care (including physical, psychological, and social interventions)
Number of subjects: 240
Study 24789702 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 240
Study 23405790 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 80
Study 23405790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20547795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose artesunate-mefloquine (AS-MQ) - 100 mg AS and 200 mg MQ/tablet daily for 3 days (days 0, 1, and 2)
Number of subjects: 50
Study 20547795 — intervention group
Group type: COMPARATOR
Intervention: Nonfixed artesunate plus mefloquine (AS-plus-MQ) - 4 mg/kg AS/day for 3 days plus 15 mg/kg MQ on day 1 and 10 mg/kg on day 2
Number of subjects: 50
Study 20547795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 50
Study 20547795 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose AS-MQ
Number of subjects: 50
Study 18543307 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR > 75.0 mL/min/1.73 m² (Group I)
Number of subjects: 346
Study 18543307 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR 60.0 to 74.9 mL/min/1.73 m² (Group II)
Number of subjects: 346
Study 18543307 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR 45.0 to 59.9 mL/min/1.73 m² (Group III)
Number of subjects: 346
Study 18543307 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment in patients with eGFR ≤ 45.0 mL/min/1.73 m² (Group IV)
Number of subjects: 346
Study 15878723 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with haloperidol (3‐10 mg/day for 2‐4 months)
Number of subjects: 10
Study 15878723 — intervention group
Group type: COMPARATOR
Intervention: Control group (Normal participants with no experience with antipsychotic drugs)
Number of subjects: 10
Study 12902363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Intervention for Trauma in Schools (10-session standardized cognitive-behavioral therapy)
Number of subjects: 126
Study 12902363 — intervention group
Group type: COMPARATOR
Intervention: Wait-list delayed intervention (control group)
Number of subjects: 126
Study 12902363 — intervention group
Group type: COMPARATOR
Intervention: Both groups received the intervention (after 6 months)
Number of subjects: 126
Study 9581986 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (Ome20)
Number of subjects: 538
Study 9581986 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (Ome10)
Number of subjects: 538
Study 9581986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study 9581986 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (Ome20) in oesophagitis patients
Number of subjects: 538
Study 9581986 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg (Ome10) in oesophagitis patients
Number of subjects: 538
Study 9581986 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment follow-up (6 months off treatment)
Number of subjects: 538
Study 1832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment group
Number of subjects: 459
Study 1832753 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment group
Number of subjects: 459
Study 1832753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 459
Study 6810013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustak 6.4 mg
Number of subjects: 32
Study 6810013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31545099 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning (n = 110)
Number of subjects: 318
Study 31545099 — intervention group
Group type: COMPARATOR
Intervention: Break-even (n = 103)
Number of subjects: 318
Study 31545099 — intervention group
Group type: EXPERIMENTAL
Intervention: Losing (n = 105)
Number of subjects: 318
Study 31545099 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity (negative and positive urgency)
Number of subjects: 318
Study 28635153 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin gel 1% applied twice daily for 9 weeks
Number of subjects: 40
Study 28635153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26890474 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain placement
Number of subjects: 106
Study 26890474 — intervention group
Group type: COMPARATOR
Intervention: No drain placement (control)
Number of subjects: 106
Study 24188499 — intervention group
Group type: EXPERIMENTAL
Intervention: pBFR (practical blood flow restriction) for elbow flexors during the first 4 weeks
Number of subjects: 20